Kiniksa Pharmaceuticals International price to free cash flow KNSA

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: 32.7×
3-year median: 43.0×
Against its 3-year history: 36th; percentile: 0 is its lowest day, 100 its highest
3-year range: 22.7× to 149×
Peer median: 50.9×

Kiniksa Pharmaceuticals International's price to free cash flow is 32.7× as of Oct 23, 2026.

That is below its 3-year median of 43.0×, close to the middle of its last 3 years.

Over that time it ranged from 22.7× in May 2026 to 149× in Nov 2024.

The median for 10 large drugmakers of a similar size is 50.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	32.7×	22.7×	35.6×
2025	31.3×	27.6×	132×
2024	130×	57.5×	149×
2023	25.2×	25.2×	30.3×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

Company	Price to free cash flow
KNSAKiniksa Pharmaceuticals International	32.7×
LGNDLigand Pharmaceuticals	46.0×
AMRXAmneal Pharmaceuticals	50.9×
ALKSAlkermes plc.	33.0×
TGTXTG Therapeutics	477×
INDVIndivior Pharmaceuticals	n/m
PTGXProtagonist Therapeutics	68.6×
ARQTArcutis Biotherapeutics	100×
CORTCorcept Therapeutics	86.8×
LQDALiquidia	25.3×
OGNOrganon	6.4×
Peer median	50.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.